FindTrial
Sign In

Construction and application of safety electronic registration platform for targeted drugs in pulmonary arterial hypertension

Construction and application of safety electronic registration platform for targeted drugs in pulmonary arterial hypertension

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200059005
Enrollment
Unknown
Registered
2022-04-22
Start date
2021-12-01
Completion date
Unknown
Last updated
2024-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Arterial Hypertension

Interventions

None listed

Sponsors

Fuwai Hospital, Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 85 Years

Inclusion criteria

Inclusion criteria: (1) Age ranges from 3 months to 85 years. (2) The results of the right heart catheter simultaneously meet the following conditions: ? mPAP=25mmHg in right heart catheter at rest ? PVR (I) 3 wood/m2 or unit ? PAWP 15 MMHG or less (3) Take at least one targeted drug or calcium antagonist for pulmonary arterial hypertension. (4) Written informed consent signed by the patient or the patient's guardian.

Exclusion criteria

Exclusion criteria: (1) Patients diagnosed with pulmonary hypertension related to left heart disease;

Design outcomes

Primary

MeasureTime frame
Adverse drug events;—

Secondary

MeasureTime frame
6 minutes walking distance (6MWD);Death,transplantation;BNP/NT-proBNP;PAH-targeted drug information;Time of clinical deterioration;Combined medication information;Echocardiography;—

Countries

China

Contacts

Public ContactLu Hua
ethannan@126.com+86 13681556900

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026